UK NICE Processes Not Fit For Orphan Drugs, Says New Report

 
• By Francesca Bruce
  
PoundSterlingPills
A report has criticized how NICE assesses orphan drug cost effectiveness • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Health Technology Assessment

More from Market Access